Clinical Trial Update: A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa [Phase 2]

View source ↗

Summary

Phase 2 study of Eltrekibart (LY3041658) in adults with moderate to severe hidradenitis suppurativa. The trial is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hidradenitis Suppurativa

Drugs mentioned

• Eltrekibart (LY3041658)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Hidradenitis Suppurativa | Phase 2 | Status: ACTIVE_NOT_RECRUITING